ABSTRACT Serum RNase (RNase I; ribonucleate 3'-pyrimidino-oligonucleotidohydrolase, EC 3.1.4.22) activity (mean ± SD) with polycytidine as substrate was determined in normal individuals (24.9 ± 3.0 units/ml) and in patients with pancreatic cancer (37.3 + 14.8), pancreatitis (38.5 ± 12.6), nonpancreatic diseases (48.7 ± 14.8), or renal failure (175.8 : 92.8 Blood drawn from patients and controls was allowed to clot and then was centrifuged; serum was removed within 2 hr of collection. The serum was stored at -20'C. Freezing, thawing, and frozen storage for at least 1 month do not affect RNase activity.
Pancreatic cancer ranks fourth in overall cancer mortality, largely-owing to the difficulty of early detection because the initial manifestations are often vague and not distinctive. New and more sensitive techniques of pancreatic imaging allow anatomic delineation of pancreatic disease, but their potential hazards, time, and expense discourage wide application. Hence, a screening test for pancreatic cancer remains one of the major objectives of research on ways to reduce cancer mortality.
Reddi and Holland (1) reported that serum RNase (ribonuclease I; ribonucleate 3'-pyrimidino-oligonucleotidohydrolase, EC 3.1.4.22) is a clinical chemical index of pancreatic cancer and would permit earlier and more reliable diagnosis when measured according to the method of Zimmerman and Sandeen (2) . However, their report did not correlate serum RNase activities with the extent of pancreatic cancers nor did it consider RNase activities in patients with abdominal conditions other than pancreatitis or gastric and colonic carcinoma. Therefore, I used the polycytidine assay used by Reddi and Holland (1) to examine the suitability of serum RNase activity as a reliable screening test for pancreatic cancer. I determined RNase activities in the sera of patients with proved cancer of varying degrees as well as sera of patients with other abdominal conditions proved not to have pancreatic cancer.
The data demonstrate that RNase measurements are not specific for pancreatic cancer nor are the values increased in patients with early, resectable disease. Serum RNase activities are normal or increased in patients who have undergone total pancreatectomy, indicating that the enzymatic activities measured by Reddi and Holland (1) are neither solely nor largely of pancreatic origin.
MATERIALS AND METHODS
Polycytidylic acid (potassium salt), bovine pancreatic RNase (type IIA and XIIA), bovine serum albumin, and Tris were purchased from Sigma. Lanthanurp oxide (Matheson) and perchloric acid (G. Frederick Smith) were of reagent grade.
Blood drawn from patients and controls was allowed to clot and then was centrifuged; serum was removed within 2 hr of collection. The serum was stored at -20'C. Freezing, thawing, and frozen storage for at least 1 month do not affect RNase activity.
The assay for serum RNase activity was based on the method for bovine pancreatic RNase first reported by Zimmerman and Sandeen (2) with the synthetic substrate polycytidine. Serum was diluted 1:1000 with 5 mM Tris at pH 7 containing 0.01% bovine serum albumin, and a 50-sl aliquot was added to a patients underwent total pancreat.c tomy for locally resectable pancreatic tumors. The neoplasms of the two other patients were locally advanced and metastatic; neither one of these two patients had obstructive jaundice because the tumor was located in the body and tail of the pancreas. None of the patients whose RNase values were increased above normal by >2 SD had resectable or "curable" pancreatic carcinomas. Table 3 shows the preoe lerative and 1-to 2-week postoperative RNase values for five patients with pancreatic cancer who did not undergo pancreatectomy. Differences between the preoperative and postoperative values are insignificant. Table 4 lists the serum RNase activities for five patients prior to and 1-2 weeks after total pancreatectomy performed for carcinoma in four patients and for chronic pancreatitis in one. At the time this report was written, the four patients with pancreatic carcinoma were surviving 2, 3, 5, and 20 months postoperatively; their RNase activities remained unchanged, and there was no clinical evidence of recurrent disease.
The relationship of serum RNase to serum creatinine values in patients with increased serum creatinine content is shown in Fig. 3 .
DISCUSSION
The presence of RNase activity in serum has been recognized since 1945 (4) , and its potential clinical significance was first studied in 1958 by Houck and Berman (5) . They found it to be increased in a number of conditions including congestive heart failure, myocardial infarction, and uremia. Levy and Rottino (6) noticed increased serum RNase activity in 71% of patients with cirrhosis, 100% with trauma, 62% with leukemia, and 30% with carcinoma (source unspecified).
Migliarese (7) first emphasized an increase of serum RNase activity in patients with malignant diseases and suggested that it might be useful as a diagnostic measure for cancer. Table 5 summarizes the results of subsequent studies of serum RNase activity in patients with malignancies. In each study, control subjects were apparently normal and did not include patients with nonmalignant diseases. Correlation of the degree of increase of RNase activity with the extent of neoplasia or thera- peutic response was variable; five studies (8-10, 12, 14) found a correlation and two (11, 12) (19) , and allowed use of a higher pH, emphasizing possible contributions of pancreatic RNase with its higher pH optimum (20) to serum activity. Serum RNase activity is not "absolutely dependent" on phosphate or citrate as stated by Reddi (20) .
Using the polycytidine RNase assay, I have been unable to confirm the conclusion that RNase activity is a "reliable biochemical marker" of pancreatic neoplasia. As a group, the RNase activities of patients with pancreatic cancer are significantly higher than those of healthy, normal controls. But (24, 25) , and platelets (26) , but the properties of their purified forms differ from those of serum RNase. Because the tissue of origin of serum RNase is unknown, increases in activity found in various pathological conditions cannot be explained on the basis of tissue of origin. Increases in activity could reflect factors other than an increase in concentration of RNase in serum. Metal ions-especially zinc, copper, and manganese (21, 27)-affect RNase activity by interacting both with the substrate to cause activation and with the enzyme to result in inhibition (21, (27) (28) (29) . Zinc-deficient animals have been shown to exhibit increased tissue RNase activities (30) . Spermine, spermidine, and putrescine stimulate RNase activity, reverse polynucleotide inhibition, and prevent aggregation of RNase (18 that clearance must reach 50-60 ml/min before an effect on serum RNase activity is seen, and this degree of renal impairment would result in abnormal serum creatinine.
In summary, serum RNase activities were increased in a group of patients with pancreatic carcinoma compared with normal, healthy, control subjects. However, the results for patients with pancreatic carcinoma, pancreatitis, and nonpancreatic disease did not differ significantly. The serum RNase activities of patients with early and curable pancreatic malignancy were not increased, and those of patients with widespread malignancy without obstructive jaundice were normal. After total pancreatectomy, patients maintained activities in the high-normal range. Hence, serum RNase activity cannot be largely of pancreatic origin nor is it a reliable biochemical marker of pancreatic carcinoma. Polynucleotides, metal ions, and polyamines significantly affect the activity of this enzyme, and alterations in serum activity may reflect either the serum milieu or changes in enzyme concentration or both. The origin of serum RNase activity remains unknown, and its increase cannot be considered diagnostic of pancreatic cancer.
